Overview

Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Status:
Completed

Trial end date:
2021-06-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the incidence of high-grade (i.e. Grade 3-4 and Grade 5 of CTCAE v4.0) adverse reactions of interest in patients with metastatic RCC who have progressed during or after receiving at least one prior systemic anti-angiogenic treatment and who are eligible for nivolumab monotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

UNICANCER

Collaborator:

Bristol-Myers Squibb

Treatments:

Angiogenesis Inhibitors
Antibodies, Monoclonal
Nivolumab